Wasko, Urszula N.
Jiang, Jingjing
Dalton, Tanner C.
Curiel-Garcia, Alvaro http://orcid.org/0000-0001-6249-3267
Edwards, A. Cole
Wang, Yingyun
Lee, Bianca
Orlen, Margo http://orcid.org/0000-0002-9834-6282
Tian, Sha
Stalnecker, Clint A. http://orcid.org/0000-0002-0570-4416
Drizyte-Miller, Kristina
Menard, Marie
Dilly, Julien http://orcid.org/0000-0002-4006-5285
Sastra, Stephen A.
Palermo, Carmine F.
Hasselluhn, Marie C. http://orcid.org/0000-0001-9765-4075
Decker-Farrell, Amanda R.
Chang, Stephanie http://orcid.org/0009-0000-2026-5215
Jiang, Lingyan
Wei, Xing
Yang, Yu C.
Helland, Ciara
Courtney, Haley
Gindin, Yevgeniy
Muonio, Karl
Zhao, Ruiping
Kemp, Samantha B.
Clendenin, Cynthia http://orcid.org/0000-0003-4535-2088
Sor, Rina http://orcid.org/0000-0003-2042-5746
Vostrejs, William P. http://orcid.org/0000-0002-1659-0186
Hibshman, Priya S.
Amparo, Amber M. http://orcid.org/0000-0003-3805-746X
Hennessey, Connor
Rees, Matthew G. http://orcid.org/0000-0002-2987-7581
Ronan, Melissa M. http://orcid.org/0000-0003-4269-1404
Roth, Jennifer A. http://orcid.org/0000-0002-5117-5586
Brodbeck, Jens
Tomassoni, Lorenzo
Bakir, Basil
Socci, Nicholas D.
Herring, Laura E. http://orcid.org/0000-0003-4496-7312
Barker, Natalie K.
Wang, Junning
Cleary, James M.
Wolpin, Brian M. http://orcid.org/0000-0002-0455-1032
Chabot, John A.
Kluger, Michael D.
Manji, Gulam A.
Tsai, Kenneth Y. http://orcid.org/0000-0001-5325-212X
Sekulic, Miroslav
Lagana, Stephen M.
Califano, Andrea
Quintana, Elsa
Wang, Zhengping
Smith, Jacqueline A. M. http://orcid.org/0000-0001-5028-8725
Holderfield, Matthew
Wildes, David http://orcid.org/0009-0009-3855-7270
Lowe, Scott W. http://orcid.org/0000-0002-5284-9650
Badgley, Michael A.
Aguirre, Andrew J. http://orcid.org/0000-0002-0701-6203
Vonderheide, Robert H. http://orcid.org/0000-0002-7252-954X
Stanger, Ben Z. http://orcid.org/0000-0003-0410-4037
Baslan, Timour
Der, Channing J. http://orcid.org/0000-0002-7751-2747
Singh, Mallika
Olive, Kenneth P. http://orcid.org/0000-0002-3392-8994
Article History
Received: 18 July 2023
Accepted: 2 April 2024
First Online: 8 April 2024
Competing interests
: J.J., Y.W., B.L., M.M., S.C., L.J., X.W., Y.C.Y., C. Helland, H.C., Y.G., K.M., R.Z., J.B., E.Q., Z.W., J.A.M.S., M.H., D.W. and M. Singh are employees and stockholders of Revolution Medicines. S.W.L., R.H.V., B.Z.S., A.J.A., C.J.D. and K.P.O. received research funding from Revolution Medicines. A.C. is founder, equity holder and consultant of DarwinHealth, a company that has licensed some of the algorithms used in this manuscript from Columbia University. Columbia University is also an equity holder in DarwinHealth. L.T. is an employee of DarwinHealth. J.M.C. receives research funding to his institution from Merus, Roche and Bristol Myers Squibb. He receives research support from Merck, AstraZeneca, Esperas Pharma, Bayer, Tesaro, Arcus Biosciences and Apexigen; he has also received honoraria for being on the advisory boards of Syros Pharmaceuticals, Incyte and Blueprint Medicines. B.M.W. has received research funding from Celgene, Eli Lilly, Novartis and Revolution Medicine and has consulted for Celgene, GRAIL and Mirati. A.J.A. has consulted for Anji Pharmaceuticals, Affini-T Therapeutics, Arrakis Therapeutics, AstraZeneca, Boehringer Ingelheim, Oncorus, Merck & Co., Mirati Therapeutics, Nimbus Therapeutics, Plexium, Revolution Medicines, Reactive Biosciences, Riva Therapeutics, Servier Pharmaceuticals, Syros Pharmaceuticals, T-knife Therapeutics, Third Rock Ventures and Ventus Therapeutics. A.J.A. holds equity in Riva Therapeutics. A.J.A. has research funding from Bristol Myers Squibb, Deerfield, Eli Lilly, Mirati Therapeutics, Novartis, Novo Ventures, Revolution Medicines and Syros Pharmaceuticals. While not directly related to this manuscript, S.W.L. declares competing interests outside consultancy and equity for Oric Pharmaceuticals, Blueprint Medicines, Mirimus, Senecea Therapeutics, Faeth Therapeutics and PMV Pharmaceuticals, and outside consultancy (no equity) for Fate Therapeutics. C.J.D. is a consultant/advisory board member for Cullgen, Deciphera Pharmaceuticals, Eli Lilly, Mirati Therapeutics, Reactive Biosciences, Revolution Medicines, Ribometrics, Sanofi and SHY Therapeutics. C.J.D. has received research funding support from Deciphera Pharmaceuticals, Mirati Therapeutics, Reactive Biosciences, and SpringWorks Therapeutics. R.H.V. has received consulting fees from BMS, is an inventor on patents relating to cancer cellular immunotherapy, cancer vaccines and KRAS immune epitopes, and receives royalties from Children’s Hospital Boston for a licensed research-only monoclonal antibody. U.N.W., C.J.D. and K.P.O. were named as inventors on a patent application filed by Columbia University pertaining to the treatment of RAS inhibitor resistant tumours. The other authors declare no competing interests.